Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Beck

Showing results (11-20 of 233) with videos related to

Pageof 24
Sort By:
Expert Opinion on Emerging Drugs|June 19, 2010
Emerging drugs for lysosomal storage diseasesMichael Beck
Acta Paediatrica (Oslo, Norway : 1992)|March 30, 2007
Update on mucopolysaccharidosis type IIMichael Beck, Ed Wraith
Acta Paediatrica (Oslo, Norway : 1992). Supplement|May 25, 2006
Assessing multiorgan disease severity: scoring systems and applicability in LSDsMichael Beck, Urs Widmer
Acta Paediatrica (Oslo, Norway : 1992). Supplement|May 25, 2006
Damage at the cellular and organ levels in LSDs: possibility for prevention/reversibility with ERTTimothy M Cox, Michael Beck
European Journal of Pediatrics|February 27, 2009
Fabry disease in children and the effects of enzyme replacement treatmentGuillem Pintos-Morell, Michael Beck
Molecular Genetics and Metabolism Reports|November 6, 2019
Comment: Why are females with Fabry disease affected?Michael Beck, Timothy M Cox
The Journal of Family Practice|December 24, 2015
Fever. Eschars on right leg and groin. Inguinal lymphadenopathy. Dx?Poonam Mathur, Shenil Shah, Michael Beck
European Journal of Human Genetics : EJHG|September 22, 2011
Clinical utility gene card for: Fabry diseaseAndreas Gal, Michael Beck, Bryan Winchester
Orphanet Journal of Rare Diseases|September 30, 2015
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatmentChristoph Kampmann, Amandine Perrin, Michael Beck
Orphanet Journal of Rare Diseases|July 14, 2016
Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatmentChristoph Kampmann, Amandine Perrin, Michael Beck
Pageof 24

Showing results (11-20 of 233) with videos related to

Sort By:
Pageof 24
Expert Opinion on Emerging Drugs|June 19, 2010
Emerging drugs for lysosomal storage diseasesMichael Beck
Acta Paediatrica (Oslo, Norway : 1992)|March 30, 2007
Update on mucopolysaccharidosis type IIMichael Beck, Ed Wraith
Acta Paediatrica (Oslo, Norway : 1992). Supplement|May 25, 2006
Assessing multiorgan disease severity: scoring systems and applicability in LSDsMichael Beck, Urs Widmer
Acta Paediatrica (Oslo, Norway : 1992). Supplement|May 25, 2006
Damage at the cellular and organ levels in LSDs: possibility for prevention/reversibility with ERTTimothy M Cox, Michael Beck
European Journal of Pediatrics|February 27, 2009
Fabry disease in children and the effects of enzyme replacement treatmentGuillem Pintos-Morell, Michael Beck
Molecular Genetics and Metabolism Reports|November 6, 2019
Comment: Why are females with Fabry disease affected?Michael Beck, Timothy M Cox
The Journal of Family Practice|December 24, 2015
Fever. Eschars on right leg and groin. Inguinal lymphadenopathy. Dx?Poonam Mathur, Shenil Shah, Michael Beck
European Journal of Human Genetics : EJHG|September 22, 2011
Clinical utility gene card for: Fabry diseaseAndreas Gal, Michael Beck, Bryan Winchester
Orphanet Journal of Rare Diseases|September 30, 2015
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatmentChristoph Kampmann, Amandine Perrin, Michael Beck
Orphanet Journal of Rare Diseases|July 14, 2016
Erratum to: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatmentChristoph Kampmann, Amandine Perrin, Michael Beck
Pageof 24